anticoagulant, curative dose for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. adjuvant therapies
vs. anticoagulant
vs. anticoagulant, prophylactic dose
vs. control

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 NCT02735707

anticoagulant, curative dose (n=1190) vs. anticoagulant, prophylactic dose (n=1054)

randomized controlled trial

Studied treatment

therapeutic-dose anticoagulation with heparin

Control treatment

usual care pharmacological thromboprophylaxis

Patients

COVID-19 mild to moderate

Method

open-label

prematurely discontinued after a planned adaptive analysis of data from 1398 patients showed that the prespecified stopping criteria for superiority of therapeutic-dose anticoagulation had been reached in both the high and low d-dimer cohorts

Remark

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open